β-thymosins and interstitial lung disease: Study of a scleroderma cohort with a one-year follow-up

Respiratory Research

Volumn 12, Issue 1, 2011, Pages

  De Santis, Maria ^a   Inzitari, Rosanna ^a   Bosello, Silvia L ^a   Peluso, Giusy ^a   Fanali, Chiara ^a   Iavarone, Federica ^a   Zizzo, Gaetano ^a   Bocci, Mario ^a   Cabras, Tiziana ^b   Messana, Irene ^b   Fuso, Leo ^a   Varone, Francesco ^a   Pagliari, Gabriella ^a   Castagnola, Massimo ^a   Ferraccioli, Gianfranco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; THYMOSIN BETA10; THYMOSIN BETA4; THYMOSIN BETA4 SULFOXIDE; THYMOSIN DERIVATIVE; UNCLASSIFIED DRUG; THYMOSIN; THYMOSIN BETA(10); THYMOSIN BETA(4); THYMOSIN BETA(4) SULFOXIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSKELETON; DISEASE COURSE; DISEASE DURATION; ECHOCARDIOGRAPHY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLITIS; LUNG ARTERY PRESSURE; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCLERODERMA; SMOKING; AGED; CASE CONTROL STUDY; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; ITALY; LUNG; LUNG DIFFUSION CAPACITY; LUNG LAVAGE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RADIOGRAPHY; REVERSED PHASE LIQUID CHROMATOGRAPHY; RISK; SYSTEMIC SCLEROSIS; TIME; VITAL CAPACITY;

ADULT; AGED; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; ODDS RATIO; PULMONARY DIFFUSING CAPACITY; ROME; SCLERODERMA, SYSTEMIC; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THYMOSIN; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 79751537902     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-22     Document Type: Article

References (30)

1. Hannappel E: b-Thymosins. Ann N Y Acad Sci 2007, 1112:21-37.
2. Huff T, Muller CS, Otto AM, Natzker R, Hannappel E: beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol 2001, 33:205-220.
3. Santelli G, Califano D, Chiappetta G, Vento MT, Bartoli PC, Zullo F, Trapasso F, Viglietto G, Fusco A: Thymosin beta-10 gene overexpression is a general event in human carcinogenesis. Am J Pathol 1999, 155:799-804.
4. Capelli E, Campo I, Panelli S, Damiani G, Barbone MG, Lucchelli A, Cuccia M: Evaluation of gene expression in human lymphocytes activated in the presence of melatonin. Int Immunopharmacol 2002,2(7):885-92.
5. Inzitari R, Cabras T, Pisano E, Fanali C, Manconi B, Scarano E, Fiorita A, Paludetti G, Manni A, Nemolato S, Faa G, Castagnola M, Messana I: HPLC-ESI-MS analysis of oral human fluids reveals that gingival crevicular fluid is the main source of oral thymosins beta(4) and beta(10). J Sep Sci 2009,32(1):57-63.
6. Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK: Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999,113(3):364-8.
7. Smart N, Rossdeutsch A, Riley PR: Thymosin b4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis 2007, 10:229-241.
8. Zhang T, Li X, Yu W, Yan Z, Zou H, He X: Overexpression of thymosin beta-10 inhibits VEGF mRNA expression, autocrine VEGF protein production, and tube formation in hypoxia-induced monkey choroid-retinal endothelial cells. Ophthalmic Res 2009,41(1):36-43.
9. Barnaeva E, Nadezhda A, Hannappel E, Sjogren MH, Rojkind M: Thymosin beta4 upregulates the expression of hepatocyte growth factor and downregulates the expression of PDGF-beta receptor in human hepatic stellate cells. Ann NY Acad Sci 2007, 1112:154-60.
10. 4 suppression of corneal NFkB: a potential anti-infllammatory pathway. Exp Eye Res 2007, 84:663-669.
11. Young JD, Lawrence AJ, MacLean AG, Leung BP, McInnes IB, Canas B, Pappin DJ, Stevenson RD: Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med 1999,5(12):1424-7.
12. Badamchian M, Damavandy AA, Damavandy H, Wadhwa SD, Katz B, Goldstein AL: Identification and quantification of thymosin β4 in human saliva and tears. Ann NY Acad Sci 2007, 1112:458-465.
13. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-90.
14. LeRoy EC, Black C, Fleishmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wolheim F: Scleroderma (systemic sclerosis): classification, subset and pathogenesis. J Rheumatol 1988, 15:202-5.
15. De Santis M, Bosello S, La Torre G, Capuano A, Tolusso B, Pagliari G, Pistelli R, Danza FM, Zoli A, Ferraccioli G: Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res 2005, 17:6. 96
16. American Thoracic Society: Standardization of Spirometry-1994 Update. Am J Respir Crit Care Med 1995, 152:1107-1136.
17. American Thoracic Society: Single breath Carbon Monoxide Diffusing Capacity (Transfer Factor). Recommendation for a standard technique-1995 Update. Am J Respir Crit Care Med 1995, 152:2185-2198.
18. Egan JJ, Martinez FJ, Wells AU, Williams T: Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 2005, 60:270-273.
19. Behr J, Furst DE: Pulmonary function tests. Rheumatol 2008, 47:65-67.
20. Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W: Assessment of disease severity and prognosis in Scleroderma. Clin Exp Rheumatol 2003, 29:42-46.
21. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Scleroderma Lung Study Research Group: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006,354(25):2655-66.
22. Hannappel E, van Kampen M: Determination of thymosin beta 4 in human blood cells and serum. J Chromatogr 1987, 26:397. 279-285
23. Mannherz HG, Hannappel E: The β-Thymosins: intracellular and extracellular activities of a versatile actin binding protein family. Cell Motil Cytoskeleton 2009, 66:839-851.
24. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D: Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004, 432:466-72.
25. 4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury. Invest Ophthalmol Vis Sci 2005, 46:2388-2395.
26. Zheng X, Wu S, Hincapie M, Hancock WS: Study of the human plasma proteome of rheumatoid arthritis. J Chromatogr A 2009, 1216:3538-3545.
27. Taggart C, Cervantes-Laurean D, Kim G, McElvaney NG, Wehr N, Moss J, Levine RL: Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem 2000,275(35):27258-27265.
28. Kowal-Bielecka O, Kowal K, Highland KB, Silver RM: Bronchoalveolar Lavage Fluid in Scleroderma Interstitial Lung Disease: Technical Aspects and Clinical Correlations. Sem Arthritis Rheum 2009,40(1):73-88.
29. Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, Henry P, Alms WJ, White B: Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999,42(6):1168-78.
30. Vasakova M, Sterclova M, Kolesar L, Slavcev A, Pohunek P, Sulc J, Skibova J, Striz I: Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. Scand J Immunol 2009,69(3):268-74.